Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Neos Therapeutics Inc    NEOS

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Neos Therapeutics : Xeris Pharmaceuticals, Inc. Appoints John P. Schmid to Board of Directors

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/12/2017 | 02:16pm CEST

Release date- 11092017 - Chicago, IL and Austin, TX - Xeris Pharmaceuticals, Inc., a specialty biopharmaceutical company developing improved and differentiated injectable therapeutics for multiple indications including diabetes, announced the appointment of John P. Schmid to the Company's Board of Directors.

'We are delighted to welcome John to the Xeris Board,' said Paul Edick, President& CEO. 'John is an accomplished executive with an impressive track record in the healthcare and biotech industry. He brings a wealth of experience and knowledge that comes from building successful life science businesses including taking two companies public and generating significant shareholder value. John will play a key role as Xeris continues executing our vision to develop and commercialize our novel XeriSol and XeriJect formulation technologies.'

About John P. Schmid

John Schmid has over 30 years of experience in financial and executive management in the biotech industry and has raised over $900 million in private and public equity and debt financings. He is currently an independent Board Member and Audit Chair for Neos Therapeutics (Nasdaq: NEOS) and AnaptysBio (Nasdaq: ANAB). Mr. Schmid also serves on the Boards of Forge Therapeutics, Patara Pharma, and Speak, Inc. Previously, he was the Chief Financial Officer of Auspex Pharmaceuticals which he joined in 2013 and took public in early 2014 before it was sold to Teva in 2015 for $3.5 billion. Prior to Auspex, Mr. Schmid co-founded Trius Therapeutics in 2004 where he served as CFO through its IPO and until its sale to Cubist Pharmaceuticals in 2013 for over $700 million. Mr. Schmid received a BA in Economics from Wesleyan University and an MBA from the University of San Diego.

About Xeris Pharmaceuticals, Inc

Xeris is a Chicago, IL and Austin, TX-based, specialty biopharmaceutical company developing improved and differentiated injectable therapeutics for multiple indications including diabetes. The Company's proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intradermal delivery of highly concentrated, non-aqueous, ready-to-inject formulations of peptides, proteins, antibodies and small molecules using auto-injectors, multi-dose pens and pumps. Xeris' proprietary formulation platforms have the potential to offer distinct advantages over existing products and formulations including: up to 1000-fold lower injection volumes, long term room-temperature stability, elimination of reconstitution and refrigeration. All of these attributes can lead to products that are easier to use by patients, caregivers, health practitioners, and can reduce costs for payers and the healthcare system.

Contact:

Steve Pieper

Tel: 312-517-1384

Email: [email protected]

Web: www.xerispharma.com

(c) 2017 Electronic News Publishing -, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NEOS THERAPEUTICS INC
09/19 NEOS THERAPEUTICS : Receives U.S. FDA Approval of Adzenys ER Extended Release Or..
09/19 NEOS THERAPEUTICS INC : Corporate News Blog - Neos Therapeutics Receives FDA’s A..
09/18 NEOS THERAPEUTICS,INC. (NASDAQ : NEOS) Files An 8-K Other Events
09/15 NEOS THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form ..
09/15 Neos Therapeutics Receives U.S. FDA Approval of Adzenys ER™ (amphetamin..
09/12 NEOS THERAPEUTICS : Xeris Pharmaceuticals, Inc. Appoints John P. Schmid to Board..
09/07 NEOS THERAPEUTICS : Announces Launch of Cotempla XR ODT Extended Release Orally ..
09/05 Neos Therapeutics Announces Launch of Cotempla XR-ODT™ (methylphenidate..
08/30 Neos Therapeutics to Participate in Three September Conferences
08/09 NEOS THERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION ..
More news
News from SeekingAlpha
09/20 BIOTECH FORUM DAILY DIGEST : Revisiting Neos Therapeutics After FDA Decision
09/18 YOUR DAILY PHARMA SCOOP : ACADIA's Growth Potential, Lexicon's Diabetes Troubles..
09/18 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
09/18 PREMARKET LOSERS AS OF 9 : 05 am
09/16 Faison's Weekend Review And Scans
Financials ($)
Sales 2017 28,6 M
EBIT 2017 -63,8 M
Net income 2017 -73,1 M
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 8,69x
EV / Sales 2018 3,93x
Capitalization 249 M
Chart NEOS THERAPEUTICS INC
Duration : Period :
Neos Therapeutics Inc Technical Analysis Chart | NEOS | US64052L1061 | 4-Traders
Technical analysis trends NEOS THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 17,7 $
Spread / Average Target 100%
EPS Revisions
Managers
NameTitle
Vipin K. Garg President, Chief Executive Officer & Director
Alan L. Heller Chairman
Richard I. Eisenstadt Chief Financial Officer
Bryant E. Fong Independent Director
Greg J. Robitaille Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
NEOS THERAPEUTICS INC48.72%249
JOHNSON & JOHNSON15.63%352 651
NOVARTIS11.88%224 990
ROCHE HOLDING LTD.6.19%220 358
PFIZER10.81%214 146
MERCK AND COMPANY11.75%177 633